News

ApoB Synthesis Inhibitor Cut LDL Cholesterol


 

From the Annual Meeting of the American College of Cardiology

The fact that patients achieve good LDL-C reductions on top of statin therapy is very encouraging, he said, noting, “The drug is not for every patient, but it could fill the need for an effective treatment in a small subset.”

Dr. Moriarty said the injectable delivery will not be a barrier to acceptance. “Patients can do these injections themselves, just like diabetes patients do. In studies I've participated in, we offer patients the opportunity to have the nurse give them the injections but most patients learn to do [the injections] themselves.”

Pages

Recommended Reading

Extreme BMI Tied to Deep Intracerebral Hemorrhage
MDedge Endocrinology
Sugar-Sweetened Drinks Tied to Blood Pressure
MDedge Endocrinology
Obesity Is Global; BP and Cholesterol Are Local
MDedge Endocrinology
Diabetic Moms' Breastfed Kids May Stay Lean
MDedge Endocrinology
First Oral ApoA-I Booster Shows Mixed Results
MDedge Endocrinology
Gastric Bypass Tied to Higher Hypoglycemia Risk
MDedge Endocrinology
Lap-Band Surgery Often Falls Short in Long Term
MDedge Endocrinology
Sleep Apnea Implicated in Deaths After Bariatric Surgery
MDedge Endocrinology
NPs Match Physicians in Weight Loss Counseling
MDedge Endocrinology
High-Intensity 'Exergames' Motivate Children
MDedge Endocrinology